# Efgartigimod for the Treatment of Guillain-Barré Syndrome

> **NCT06885762** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Zhongming Qiu** · enrollment: 20 (estimated)

## Conditions studied

- Guillain-Barre Syndrome (GBS)

## Interventions

- **DRUG:** efgartigimod

## Key facts

- **NCT ID:** NCT06885762
- **Lead sponsor:** Zhongming Qiu
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-13
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06885762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06885762, "Efgartigimod for the Treatment of Guillain-Barré Syndrome". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06885762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*